We are excited to bring you new information on our Bladder Cancer Program, hosted by Ramy Sedhom, MD. For this…
Browsing: Bladder
We are excited to bring you new information in our Bladder Cancer Program, hosted by Ramy Sedhom, MD.For this video,…
Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
Keyan Salari, MD @KeyanSalari of Massachusetts General Hospital @MGHUrology discusses 5-alpha reductase inhibitors and risk of overall and fatal bladder…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses if switch maintenance immunotherapy is a standard base treatment…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC answers what is the role of a switch maintenance immune…
Matthew Galsky, MD of Mount Sinai Health System @IcahnMountSinai @MountSinaiNYC discusses switch maintenance immunotherapy, significantly slows the worsening of a…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Andrew Krivoshik, MD of @AstellasUS discusses the FDA breakthrough therapy for PADCEV in combination with pembrolizumab in first-line advanced bladder…
Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial – – Astellas Pharma Inc. (TSE: 4503,…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this first video of 2019, Dr.…
GRACE is excited to bring you new information in our Bladder Cancer Program. For this video, Dr. Ramy Sedhom introduces…
·         At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS)…
Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO. #ESMO2019
Andrew Krivoshik, MD of @AstellasUS discusses the EV_103 phase I trial in locally advanced and first- and second-line metastatic urothelial…
– Food & Drug Administration Sets Prescription Drug User Fee Action Date for March 15, 2020 – Â BOTHELL, Wash.…
he Tisch Cancer Institute Deepens Bladder Cancer Care With New Center of Excellence  (New York – September 12, 2019) The…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Bradley McGregor MD, Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, GU Network Liaison, Dana Farber…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab…
Dr. Cora Sternberg Of Weill Cornell Medicine and NewYork-Presbyterian discusses the broader implications of the SAUL study. Background: Atezo, a…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Challenges Using…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Role Of…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Molecular Characterization &…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses The Latest In…
Yair Lotan, MD, Professor of Urology, Chief of Urologic Oncology, University of Texas Southwestern Medical Center, Discusses Outcomes Of KEYNOTE…
Speaking from the 2018 Genitourinary Cancers Symposium in San Francisco, CA, Peter Black, MD, of the University of British Columbia,…
BCG immunotherapy is one of the primary treatment options for bladder cancer patients who are ineligible for cystectomy. However, some…
Treatment for muscle-invasive bladder cancer has evolved as medical knowledge has expanded. Jeanny Aragon-Ching, MD, FACP, from Inova Schar Cancer…
In this video, Peter Black, MD, of the University of British Columbia, Vancouver, Canada, speaks to us about the use…
Jeanny Aragon-Ching, MD, FACP, of Inova Schar Cancer Institute, Falls Church, VA, discusses the differences in survival rates of non-urothelial…
The European Medicines Agency have announced their recommendation to restrict the use of pembrolizumab and atezolizumab to the first-line treatment…
The ABACUS trial (NCT02662309), an investigator-initiated Phase II study investigating the safety and efficacy of two cycles of neoadjuvant atezolizumab…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here,…
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how…
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the first results of the primary analysis of…
Nataliya Mar, MD, UC Irvine Health, shares her Urothelial Carcinoma Abstracts | Enfortumab, Erdafitinib were Effective Based on Data at…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting…
A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO)…
Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society…
Dr. Daniel Goldstein reviews provocative and highly promising results with enfortumab, an inhibitor of nectin-4, as a treatment for advanced…
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these…
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including important studies evaluating the efficacy of neoadjuvant immunotherapy…
Jeanny B. Aragon-Ching, MD, FACP, explains reliable molecular markers that can help identify high-risk muscle-invasive bladder cancer patients who should…
Gary D. Steinberg, MD, explains whether FGFR inhibitors in metastatic bladder cancer have the potential to be practice changing.
Jeanny B. Aragon-Ching, MD, FACP, discusses how new guidelines have changed the treatment of advanced metastatic bladder cancer.